Fortis Malar Hospitals Q4 FY26 Results: Loss Rs 0.05 Cr, Revenue Rs 0.00 Crore

May 19, 2026
Posted by: Ankit Jaiswal
Category: News

Fortis Malar Hospitals Q4 FY26 results were declared on May 18, 2026, at the board of directors meeting. Fortis Malar Hospitals reported a net loss of Rs 0.05 crore for the quarter ended March 31, 2026, Q4 FY26 (results declared May 18, 2026), on revenue of Rs 0.00 crore. Fortis Malar Hospitals operates in the multi-speciality hospital and healthcare services sector. Investors tracking Fortis Malar Hospitals Q4 FY26 will find a complete financial analysis and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Table of Contents

Fortis Malar Hospitals Q4 FY26 Financial Highlights

Metric	Q4 FY26	Comparison
Net Loss	Rs 0.05 crore	Q4 FY26 (results declared May 18, 2026)
Revenue from Operations	Rs 0.00 crore	Quarter ended March 31, 2026
Ticker		Sector: Healthcare

Fortis Malar Hospitals Q4 FY26 Performance Analysis

Fortis Malar Hospitals Q4 FY26 reflects the company’s operational performance during the January to March 2026 quarter. Fortis Malar Hospitals is a leading multi-speciality hospital and healthcare services company whose Q4 FY26 print sets the baseline for FY27 guidance. The reported loss reflects ongoing challenges; management guidance on the FY27 recovery trajectory will be the key watch point. Q4 January to March is typically a seasonally strong quarter for Indian companies, driven by year-end government procurement and project completion cycles.

The path to profitability in FY27 depends on volume recovery, cost reduction, and strategic business initiatives. Track Fortis Malar Hospitals on the Univest Screener for live data.

Check the Univest Screener for live data

Key Factors for the Company

Revenue and Sector Dynamics

Fortis revenue of Rs 0.00 crore reflects the company’s execution in the multi-specialty hospital and healthcare services space. India’s sustained economic growth of 6.5%+ and robust domestic demand across sectors provide a supportive backdrop for FY27 business planning.

Profitability and Margin Trends

The company’s net loss of Rs 0.05 crore Q4 FY26 (results declared May 18, 2026) demonstrates near-term margin challenges. The company’s FY27 strategy to restore profitability through volume growth and cost optimisation will be closely monitored by investors.

FY27 Business Outlook

Following the firm results, management guidance on FY27 revenue, order book, and strategic priorities will be key catalysts. Download the Univest iOS App or Univest Android App to receive SEBI-registered analyst research on Fortis Malar Hospitals.

Frequently Asked Questions on Fortis

What is the company’s PAT?

Ans. Fortis reported a net loss of Rs 0.05 crore Q4 FY26 (results declared May 18, 2026). Results declared May 18, 2026. Full details from NSE/BSE regulatory filings. Verify all data before investing.

What is the company’s revenue?

Ans. The firm’s revenue from operations was Rs 0.00 crore for the quarter ended March 31, 2026. Track live on the Univest Screener.

When were Fortis results announced?

Ans. The company results were announced on May 18, 2026, at the board meeting approving audited Q4 and FY26 financial statements for the year ended March 31, 2026.

Is Fortis Malar Hospitals a good investment after Q4 FY26?

Ans. Investment decisions require individual assessment of fundamentals, valuation, sector dynamics, and personal risk tolerance. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before investing.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.